SentryX

What SentryX does

SentryX B.V. is a clinical-stage biopharmaceutical company founded in 2017 as a spin-out from the University Medical Center Utrecht, developing non-opioid local pain treatments for major surgery. Its core technology is the proprietary Implantable Local Anesthetics (ILA) platform: a strong, highly elastic, biodegradable hydrogel ring that can be loaded with small-molecule drugs and tailored for sustained local release over multiple days. The lead product candidate, BR-003, is a bupivacaine-loaded version of this hydrogel ring designed for co-implantation with commercially available pedicle screws in spine fixation surgery, delivering local anesthetic for 72+ hours at the surgical site without changing the surgical workflow. BR-003 is positioned as first-in-class for spine surgery and has demonstrated 49% reduction in pain scores and 42% reduction in opioid use at 72 hours in a Phase 1b study of 11 treated patients versus 41 observational controls.

The platform is protected by six patent families with first US patent granted March 2023 and European patent allowed, supported by peer-reviewed publications in Nature Scientific Reports, Regional Anesthesia & Pain Medicine, Acta Biomaterialia, and others. SentryX has raised €3.2M in seed funding (April 2021, including Utrecht Health Seed Fund) and €15.5M in non-dilutive EIC Accelerator funding (April 2023). The company is pre-revenue: BR-003 is investigational and has not been approved by the FDA, EMA, or any other regulatory authority. The commercial model is planned as direct sales of BR-003 (a combination medical device + drug product) to hospitals and surgical centers performing spine fixation surgery in Europe and the United States, with platform extension to other orthopedic procedures (joint replacement, fracture fixation) representing a larger ~25 million musculoskeletal procedures-per-year addressable market.

Name

SentryX

Legal name

SentryX B.V.

Website

https://sentryx.nl

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

SentryX is a Netherlands-based clinical-stage biopharmaceutical company developing BR-003, a biodegradable bupivacaine-loaded hydrogel ring for co-implantation with pedicle screws to deliver non-opioid, 72+ hour local pain relief after spine fixation surgery, targeting ~1.2M annual low-back surgeries in Europe and the US.

Ownership category

akta.pro rank

Product category

Post-Surgical Pain Management Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Spine Implants & Motion Preservation (Fusion/Disc/Interspinous) (HLAHAEAC)

akta.pro secondary industries

Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB), Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH), Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA), Fibrin Sealants & Plasma-Derived Surgical Hemostats (Fibrinogen/Thrombin) (HLAIAHAG)

Keywords

• Implantable local anesthetics
• Non-opioid pain management
• Spine surgery devices
• Drug-eluting implants
• Biodegradable hydrogel

Headquarters

HQ city

Austerlitz

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Pre-revenue clinical-stage development: SentryX is a clinical-stage biopharmaceutical company; BR-003 is investigational and has not been approved by the FDA, EMA, or any other regulatory authority. The company is currently pre-revenue and funded through grants, equity (seed and EIC Accelerator), and is preparing for a pivotal Phase 3 trial ahead of future commercialization. Future revenue model is expected to center on product/hardware sales (medical device + drug combination product) to hospitals and surgical centers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

SentryX develops BR-003, an investigational surgical pain blocker consisting of a strong, highly elastic, biodegradable hydrogel ring loaded with bupivacaine that is co-implanted with commercially available pedicle screws during spine fixation surgery. The product releases a well-established local anesthetic locally for 72+ hours at the surgical site, blocking pain signals without changing the existing surgical workflow. BR-003 is investigational and has not yet been approved by the FDA, EMA, or any other regulatory authority.

Product overview

SentryX's offering is a single clinical-stage biopharmaceutical/medtech platform built around its proprietary ILA-technology (Implantable Local Anesthetics), an elastic, biodegradable hydrogel loaded with small-molecule drugs (notably bupivacaine) that enables sustained multi-day local drug delivery at a surgical site. The platform is realized today in one lead investigational product candidate, BR-003, a bupivacaine-loaded hydrogel ring that is co-implanted with commercially available pedicle screws to provide non-opioid postsurgical pain relief in spine fixation surgery for 72+ hours without changing the surgical workflow. BR-003 is positioned as first-in-class for spine surgery and is intended to serve as the template for adapting the underlying ILA-technology platform to other orthopedic indications such as joint replacement and fracture fixation.

Differentiator

Problem solved

Functional benefit

Brands

• BR-003: SentryX's lead investigational product candidate: a bupivacaine-loaded, highly elastic, biodegradable hydrogel ring designed for sustained local delivery of a local anesthetic over 72+ hours following co-implantation with pedicle screws in spine fixation surgery. First-in-class for spine surgery.

Products and services

• BR-003 BR-003 is SentryX's lead investigational surgical pain blocker: a strong, highly elastic, biodegradable hydrogel ring loaded with bupivacaine that is co-implanted with commercially available pedicle screws to deliver sustained local bupivacaine release for 72+ hours, blocking pain signals at the surgical site in spine fixation surgery. It is designed for hospitals, spine surgeons and surgical centers performing spine fixation and integrates with existing pedicle screws without changing placement, function, or the rest of the surgical workflow. It is investigational and has not been approved by the FDA, EMA, or any other regulatory authority.

Quantifiable outcome

• 49% reduction in pain scores at 72 hours post-spine surgery (Phase 1b, 11 treated vs 41 observational cohort)
• +5 more outcomes

Named customers2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered minor, core and flagship.

• Provincie UtrechtminorGTM or Marketing Partner · 1 April 2026Regional government and ecosystem partner; featured SentryX in an article on its work developing surgical pain blockers and on what European support means for innovative SMEs in the Utrecht region. SentryX is a member of the Utrecht Science Park community.
• HollandBIOminorGTM or Marketing Partner · 1 March 2026Dutch trade association for innovative life sciences welcomed SentryX as a member; co-hosted a roundtable in March 2026 with Dutch policymakers on the future of biotech in the Netherlands and Europe, with CEO Bas Oosterman participating alongside The Protein Brewery and Novonesis.
• Convoi and Endurance Service B.V.minorOthers · 1 February 2026Delivery and installation partners supporting arrival and placement of a new machine for SentryX's scaled-up production line (February 2026).
• Jan Sigger, Nadine Maalouf, Koen de Heus (Supervisory Board)Others · 1 May 2025
• Hans Schikan (Informal Advisor / Investor)coreOthers · 1 January 2024Hans Schikan joined SentryX as investor and informal strategic advisor in January 2024; brings 30+ years biopharmaceutical development, commercial and leadership experience; Top Team member for the Dutch Topsector for Life Sciences & Health and Termeer Foundation mentor.
• Anne Hoogstraten (Chief People Officer)minorOthers · 1 December 2023Appointed as SentryX's first Chief People Officer in December 2023 to scale-up and professionalize internal organization; previously change consultant and leader at Korn Ferry Advisory Netherlands.
• Alex Vaccaro (Strategic Advisor)coreOthers · 1 October 2022Dr. Alex Vaccaro (president of Rothman Orthopaedic Institute, professor and chairman of Orthopedic Surgery at Thomas Jefferson University) joined SentryX as strategic advisor in October 2022 to provide guidance during clinical development and implementation of BR-003.
• Radboud University Medical Center (RadboudUMC) — Medical Innovation and Technology GroupcoreStrategic or Co-development Partner · 1 September 2022Collaboration to develop an HTA (Health Technology Assessment) model that connects medical performance of BR-003 to expected benefits for patient, hospital and society; supports early HTA-modeling expertise and validates against clinical trial results and post-marketing surveillance. PhD candidate Hein Jonkman studies the impact of pain management on early mobilization and recovery, costs, and long-term outcomes.
• Dutch Cancer Society (KWF) — via UMC Utrecht 'CODED' projectminorStrategic or Co-development Partner · 1 April 2022UMC Utrecht received €600,000 KWF research grant for the 'CODED' project (Controlled Release of Drugs in Glioblastoma). Project employs SentryX's proprietary hydrogel technology as a hemostatic adhesive drug carrier for localized controlled release of therapeutics to brain tissue following glioblastoma resection; SentryX is a partner. Project ran ~3 years from H2 2022.
• University Medical Center Utrecht (UMC Utrecht)flagshipStrategic or Co-development Partner · 1 January 2017SentryX was founded in 2017 as a spin-out from UMC Utrecht where co-founder Prof. Dr. Jorrit-Jan Verlaan works as a spine surgeon. UMC Utrecht continues to be a deep research and clinical collaboration partner; Prof. Marianna Tryfonidou, Prof. Raymond Schiffelers and Prof. Jos Malda at UMC Utrecht serve as Scientific Advisors. Joint publications on hydrogel technology and bupivacaine delivery.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Camurus: Swedish specialty pharma with a FluidCrystal depot technology for sustained-release drug delivery, including bupivacaine products in development. Comparable as an established European-based company with sustained-release local drug delivery technology relevant to SentryX's ILA platform.
• Vertex Pharmaceuticals: Vertex received FDA approval for Journavx (suzetrigine/VX-548), an oral non-opioid NaV1.8 inhibitor for acute pain, in January 2025. A broad incumbent entrant into non-opioid postsurgical pain with substantially greater resources, validating the market SentryX targets but representing a major competitive threat.

Emerging players

• Latigo Biotherapeutics: Clinical-stage biotech developing non-opioid pain therapeutics including Nav1.7/1.8 inhibitors for acute and chronic pain. Comparable as an emerging non-opioid pain company targeting postsurgical pain, with similar clinical-stage profile to SentryX.
• SiteOne Therapeutics: Clinical-stage company developing selective sodium channel inhibitors (Nav1.7) for non-opioid pain management. Comparable emerging player in non-opioid postsurgical pain space with similar clinical-stage development profile.
• Trevena: Developed Olinvyk (oliceridine), an IV opioid with a differentiated safety profile for acute pain in hospital settings. Comparable as a company developing novel analgesic agents for the postsurgical pain market with regulatory experience in the indication.
• Concentric Analgesics: Clinical-stage company developing CA-008 (vocapsaicin), a non-opioid long-acting analgesic for acute postsurgical pain. Comparable target indication (postsurgical pain) and similar clinical-stage status, though using a TRPV1 agonist mechanism rather than local anesthetic.

Direct peers

• Heron Therapeutics: Heron developed Zynrelef (HTX-011), a bupivacaine/meloxicam extended-release combination approved for postsurgical pain. Directly comparable to BR-003 as a non-opioid, sustained-release local anesthetic for postsurgical pain management in the same surgical setting.
• Pacira BioSciences: Pacira's lead product Exparel is a long-acting, sustained-release bupivacaine formulation marketed for postsurgical pain — the most direct direct competitor to SentryX's BR-003 in the non-opioid postsurgical pain space, though delivered via injection rather than an implanted device.
• Innocoll Pharmaceuticals: Developed Xaracoll, a bioresorbable collagen matrix implant delivering bupivacaine at the surgical site for postsurgical pain. Closely comparable as a bupivacaine-eluting implantable matrix for postsurgical pain, though targeted at soft tissue / hernia surgery rather than spine.
• Durect Corporation: Developed Posimir (bupivacaine extended-release solution) for postsurgical pain. Comparable as a sustained-release local anesthetic program targeting the same unmet need of opioid reduction after surgery, though using a different delivery technology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sentry-x
• Facebookfacebook.com/SentryX-267008320920937

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SentryX